{"nctId":"NCT00122382","briefTitle":"Remission and Joint Damage Progression in Early Rheumatoid Arthritis","startDateStruct":{"date":"2005-07"},"conditions":["Rheumatoid Arthritis"],"count":1052,"armGroups":[{"label":"ABA + MTX","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Abatacept","Drug: methotrexate"]},{"label":"Placebo (PLA) + MTX","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Abatacept","Drug: placebo","Drug: methotrexate"]}],"interventions":[{"name":"Abatacept","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"methotrexate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of rheumatoid arthritis (RA) \\<=2 years; MTX naive or \\<=10 mg/wk for \\<=3 weeks. No dose within 3 months prior to informed consent.\n* C-Reactive Protein (CRP) \\>= 4.5 mg/L (after amendment)\n* Rheumatoid factor or anti-cyclic citrullinated peptide antibody (anti-CCP) positive\n* Tender joints \\>=12 and swollen joints \\>=10\n\nExclusion Criteria:\n\n* Women and men who are not willing to use birth control\n* Diagnosed with other rheumatic disease\n* History of cancer within 5 years\n* Active tuberculosis\n* Treatment with another investigation drug within 28 days\n* Active bacterial or viral infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Number of Participants With American College of Rheumatology (ACR) 50 Response at Month 12","description":"ACR 50 response was defined as a 50% improvement from baseline to Month 12 in tender and swollen joint counts and 50% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function), and 1 acute phase reactant value \\[ie, CRP\\].","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Major Clinical Response (MCR) at Month 12","description":"MCR was defined as 6 months of consecutive ACR 70 response at Month 12. ACR 70, the American College of Rheumatology (ACR) definition of 70% improvement was based on a 70% improvement (compared to baseline values) in tender and swollen joint counts and 70% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function, and 1 acute phase reactant value \\[ie, CRP\\]).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change From Baseline in DAS-28-CRP Score to Month 12","description":"DAS 28-CRP is a continuous variable that is a composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, CRP in milligrams/Liter (mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 to 10, indicating the current activity of the rheumatoid arthritis. A DAS28 \\>5.1=high disease activity; \\<3.2=low disease activity; \\<2.6=remission. Change from Baseline=Post-baseline - Baseline value; Adjusted for baseline value.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.22","spread":"0.09"},{"groupId":"OG001","value":"-2.49","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 12","description":"Physical function was evaluated using the HAQ-disability index (HAQ-DI), a questionnaire with 20 questions assessing function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. The 8 category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). Higher scores indicate greater dysfunction. HAQ response=improvement of at least 0.3 units from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"184","spread":null},{"groupId":"OG001","value":"157","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Short Form 36 (SF-36) From Baseline to Month 12","description":"The SF-36 covers 8 health dimensions: 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from 0 to 100, with a higher score indicating better quality of life. Two summary scores (physical and mental component summaries) were produced taking a weighted linear combination of the 8 individual subscales. Change from Baseline=Post-baseline - Baseline value; adjusted for baseline value.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.68","spread":"0.62"},{"groupId":"OG001","value":"9.18","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.15","spread":"0.64"},{"groupId":"OG001","value":"6.34","spread":"0.64"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Radiographic Erosion and Joint Space Narrowing (JSN) Scores to Month 12","description":"To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The erosion score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). The joint space narrowing score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). Higher scores indicated more damage. Change from baseline = Post-baseline - Baseline value","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.48","spread":"6.15"},{"groupId":"OG001","value":"4.81","spread":"5.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"1.39"},{"groupId":"OG001","value":"0.89","spread":"2.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"3.99"},{"groupId":"OG001","value":"1.86","spread":"3.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.53"},{"groupId":"OG001","value":"0.17","spread":"0.54"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses in the Double-blind Period as Analyzed by Enzyme-linked-immunosorbent Serologic Assay (ELISA)","description":"Serum samples were analyzed by ELISA to detect antibodies against the whole molecule (both CTLA4 and Ig \\[anti-abatacept antibody\\]) or solely to CTLA4 (anti-CTLA4-T antibody). Reported as titer, the reciprocal of the sample dilution which yielded a signal equivalent to the statistically set cut point for the assay. For the anti-abatacept assay, minimum required dilution is 400-fold, therefore seronegative samples are those \\< lowest reportable titer (\\<400). For the anti-CTLA4-T assay, minimum required dilution is 25-fold, therefore seronegative samples are those \\< lowest reportable titer (\\<25).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12","description":"Number of participants who achieved remission at Month 12 of treatment, as defined by a Disease Activity Score (DAS) 28-CRP score of \\<2.6. DAS 28-CRP is a continuous measure, a composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, CRP (in mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 (best) to 10 (worst), indicating the current activity of the rheumatoid arthritis. A DAS28 \\>5.1 = high disease activity; \\<=3.2 = low disease activity; \\<2.6 = remission.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Radiographic Total Score to Month 12","description":"To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and joint space narrowing (JSN). The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.50","spread":"9.52"},{"groupId":"OG001","value":"6.67","spread":"8.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"1.74"},{"groupId":"OG001","value":"1.06","spread":"2.45"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs During the Open-Label Period","description":"AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"345","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events Reported During the Open-Label Period","description":"SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses During the Open-Label Period (From Month 12 to Month 24) as Analyzed by ELISA","description":"Serum samples were analyzed by ELISA to detect antibodies against the whole molecule (both CTLA4 and Ig \\[anti-abatacept antibody\\]) or solely to CTLA4 (anti-CTLA4-T antibody). Reported as titer, the reciprocal of the sample dilution which yielded a signal equivalent to the statistically set cut point for the assay. For the anti-abatacept assay, minimum required dilution is 400-fold, therefore seronegative samples are those \\< lowest reportable titer (\\<400). For the anti-CTLA4-T assay, minimum required dilution is 25-fold, therefore seronegative samples are those \\< lowest reportable titer (\\<25).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 24","description":"Physical function was evaluated using the HAQ-disability index (HAQ-DI), a questionnaire with 20 questions assessing function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. The 8 category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). Higher scores indicate greater dysfunction. HAQ response=improvement of at least 0.3 units from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"178","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Radiographic Total, Erosion and JSN Scores to Month 24","description":"To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. Change from baseline = Postbaseline - baseline value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.91","spread":"6.48"},{"groupId":"OG001","value":"5.49","spread":"5.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"2.31"},{"groupId":"OG001","value":"1.40","spread":"3.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.83","spread":"3.82"},{"groupId":"OG001","value":"1.75","spread":"3.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"1.03"},{"groupId":"OG001","value":"0.34","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.73","spread":"9.50"},{"groupId":"OG001","value":"7.24","spread":"8.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":"3.22"},{"groupId":"OG001","value":"1.75","spread":"3.59"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With SAEs With an Outcome of Death During the Open-label Period","description":"Any untoward medical occurrence (SAE) that resulted in death","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence Rates of Autoimmune Disorders in ABA-Treated Participants","description":"The incidence rates of autoimmune disorders are defined as the (number of patients experiencing the event/exposure within the period)\\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":null},{"groupId":"OG001","value":"1.30","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence Rates of Infections and Infestations of Adverse Events in ABA-Treated Participants","description":"The incidence rates of infections and infestations are defined as the (number of patients experiencing the event /exposure within the period)\\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.37","spread":null},{"groupId":"OG001","value":"66.68","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence Rates of Malignant Neoplasm Adverse Events in ABA-Treated Participants","description":"The incidence rates of malignant neoplasms are defined as the (number of patients experiencing the event /exposure within the period)\\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With a Serious Acute-Infusional AE of Anaphylactic Shock During Open-Label Period","description":"There were 107 Prespecified, acute-infusional SAEs (occurring within 1 hour after the start of study drug infusion) pre-specified in the protocol; anaphylactic shock was the only one occuring in this study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Select Blood Chemistry Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period","description":"Number of subjects with high liver function and kinedy tests: alkaline phosphatase (ALP) \\>2x upper limit of normal (ULN) or if pretreatment (PRE-RX) \\>ULN then \\>3x PRE-RX; aspartate aminotransferase (AST) \\>3x ULN or if PRE-RX \\>ULN then \\>4x PRE-RX; alanine aminotransferase (ALT) \\>3x ULN or if PRE-RX \\>ULN then \\>4x PRE-RX; g-glutamyl transferase (GGT)\\>2x ULN or if PRE-RX \\>ULN then \\>3x PRE-RX; total bilirubin \\>2x ULN or if PRE-RX \\>ULN then \\>4x PRE-RX; blood urea nitrogen \\>2x PRE-RX; creatinine \\>1.5x PRE-RX.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Hematology Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period","description":"Marked abnormalities in hemoglobin \\>3 g/dL decrease from PRE-RX; hematocrit \\<0.75x PRE-RX; erythrocytes \\<0.75x PRE-RX; platelet count \\<0.67x lower limit of normal (LLN) or \\>1.5x ULN or if PRE-RX \\<LLN then \\<0.5x PRE-RX and \\<100,000/mm3; leukocytes \\<0.75x LLN or \\>1.25x ULN or if PRE-RX \\<LLN then \\<0.8x PRE-RX or \\>ULN if PRE-RX \\>ULN then \\>1.2x PRE-RX or \\<LLN; neutrophils if value \\<1.00 x10\\^3 c/uL; lymphocytes if value \\<.750 x10\\^3 c/uL or if value \\>7.50 x10\\^3 c/uL; monocytes if value \\>2000/MM3; basophils if value \\>400/mm3; eosinophils if value \\>.750 x10\\^3 c/uL","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Without Radiographic Progression (as Measured by in Erosion Scores, JSN Scores, and Total Scores) From Baseline at Month 24","description":"Participants with no radiographic progression (defined as change in score \\<=0 or \\<=0.5), from baseline to Month 24. To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"166","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Without Radiographic Progression (as Measured by in Erosion Scores, JSN Scores, and Total Scores) at Month 24 in Participants Without Progression at Month 12","description":"Participants with no radiographic progression ((defined as change in score \\<=0 or \\<=0.5), sustained from Month 12 and Month 24. To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"169","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"163","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Difference Observed in Change From Baseline to Month 12 and Between Month 12 and Month 24 in Radiographic Scores (Total Score)","description":"Mean difference observed in change from baseline to Month 12 and between Month 12 and Month 24 in radiographic scores (Total Score). To assess joint damage, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":"0.13"},{"groupId":"OG001","value":"0.18","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Reported During the Double-blind Period","description":"AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"217","spread":null},{"groupId":"OG001","value":"211","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During the Double-blind Period","description":"Number of participants with laboratory values (hematology, liver and kidney functions, electrolytes, glucose tests, protein tests, metabolite tests, and urine chemistry tests) considered markedly abnormal according to prespecified protocol criteria","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":256},"commonTop":["NAUSEA","HEADACHE","UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","INFLUENZA"]}}}